Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...

By Yahoo! Finance | Nov 15, 2024 at 02:11 AM EST

Cash and cash equivalents stood at around $427 million by the end of the third quarter. The company discusses the overlap of sites for SO1 and Solar studies, aiming for a differentiated product label for their drug, and providing updates on Solar's enrollment progress for a seamless transition with a steady recruitment pace.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.